Möchten Sie immer auf dem neuesten Stand bleiben?

Vertero appoints Jeffrey Kasten as Chief Business Officer to drive strategic partnerships and accelerate portfolio strategy in neurodegenerative diseases.

Longeveron granted Canadian patent for method of using stem cells to treat patients with aging-related frailty and also for the treatment of NIDCM.

Fort Myers, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- TeleSpecialists, a leading provider of digital neurology services, announced the launch of its inaugural clinical immersion symposium, "A Day in...

New advisory board brings further world-class expertise in oncology, neurology, geographic market expansion, and AI enabled clinical trial delivery to support biotech innovators LETCHWORTH GARDEN...

Centre for Neuro Skills (CNS), a premier provider of treatment for traumatic and acquired brain injury, has opened its new clinic in Plano, Texas.

CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...

Dublin, Nov. 27, 2025 (GLOBE NEWSWIRE) -- The "Hepatic Encephalopathy Market - A Global and Regional Analysis: Focus on Type, Treatment Type, and Region - Analysis and Forecast, 2025-2035" has been...

Boston, Nov. 27, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “AI in Neurology: Global Markets” is estimated to increase from $705.6 million in 2025 to $2.5 billion by...

Vertero announces initiation of Phase 1 study of VT-5006, a first-in-class selective small molecule therapy for Parkinson’s disease.

Dr. Mark J. Ashley, Founder and Executive Chairman of the Board of Centre for Neuro Skills, honored as BIAA 2025 Luminary of the Year.